CN111094327A - Bpifb4蛋白的用于神经元疾病和损伤的vtft同种型 - Google Patents

Bpifb4蛋白的用于神经元疾病和损伤的vtft同种型 Download PDF

Info

Publication number
CN111094327A
CN111094327A CN201880052353.2A CN201880052353A CN111094327A CN 111094327 A CN111094327 A CN 111094327A CN 201880052353 A CN201880052353 A CN 201880052353A CN 111094327 A CN111094327 A CN 111094327A
Authority
CN
China
Prior art keywords
protein
disease
seq
vtft
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880052353.2A
Other languages
English (en)
Chinese (zh)
Inventor
安尼巴莱·亚历山德罗·普卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lgv1 Co ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN111094327A publication Critical patent/CN111094327A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201880052353.2A 2017-08-16 2018-08-16 Bpifb4蛋白的用于神经元疾病和损伤的vtft同种型 Pending CN111094327A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17186528 2017-08-16
EP17186528.0 2017-08-16
PCT/EP2018/072184 WO2019034723A1 (en) 2017-08-16 2018-08-16 VTFT ISOFORM OF BPIFB4 PROTEIN INTENDED FOR USE IN NEURONAL DISEASES AND INJURIES

Publications (1)

Publication Number Publication Date
CN111094327A true CN111094327A (zh) 2020-05-01

Family

ID=59713793

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880052353.2A Pending CN111094327A (zh) 2017-08-16 2018-08-16 Bpifb4蛋白的用于神经元疾病和损伤的vtft同种型

Country Status (8)

Country Link
US (1) US12311009B2 (https=)
EP (1) EP3668891B1 (https=)
JP (1) JP2020531047A (https=)
CN (1) CN111094327A (https=)
AU (1) AU2018317807A1 (https=)
CA (1) CA3109159A1 (https=)
ES (1) ES2970198T3 (https=)
WO (1) WO2019034723A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4434534A1 (en) 2023-03-22 2024-09-25 ADvantage Therapeutics, Inc. Klotho mrna

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079269A2 (en) * 2000-04-18 2001-10-25 Merck Patent Gmbh Lipid binding protein 4
WO2002063008A2 (en) * 2001-02-08 2002-08-15 Incyte Genomics, Inc. Intracellular signaling molecules
US20040092715A1 (en) * 2002-02-07 2004-05-13 Li Ding Intracellular signaling molecules
CN104955836A (zh) * 2012-12-28 2015-09-30 安尼巴莱·亚历山德罗·普卡 Bpifb4蛋白的变体

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
AU2144999A (en) * 1998-01-13 1999-08-02 Claude Gravel Viral vectors encoding neurofilament heavy proteins and their use
WO1999036560A2 (en) * 1998-01-13 1999-07-22 Julien Jean Pierre Viral vectors encoding neurofilament light proteins and their use
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
AU2002313992B2 (en) * 1998-08-31 2006-09-21 Pro-Neuron, Inc. Compositions and Methods for Treatment of Mitochondrial Diseases
AU6234700A (en) * 1999-07-27 2001-02-13 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
US6515197B1 (en) * 2000-08-24 2003-02-04 Cedars-Sinai Medical Center Transgenic mouse expressing a polynucleotide encoding a human ataxin-2 polypeptide
GB0100119D0 (en) * 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
WO2002090504A2 (en) * 2001-05-03 2002-11-14 Curagen Corporation Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
WO2003004660A1 (en) * 2001-07-03 2003-01-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods of administering vectors to synaptically connected neurons
AU2002359284A1 (en) 2001-12-17 2003-06-30 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
NZ533833A (en) * 2001-12-21 2008-01-31 Salk Inst For Biological Studi Targeted retrograde gene delivery to motor neurons
EP1489423A1 (en) * 2003-06-20 2004-12-22 Universite Louis Pasteur Use of mitochondrial uncoupling proteins for diagnostic, prevention and treatment of diseases involving neuromuscular affection
WO2005095610A1 (en) * 2004-03-31 2005-10-13 Agt Biosciences Limited Nucleic acid expressed in the hypothalamus or muscle tissue and uses thereof in diagnoses
WO2006022619A2 (en) * 2004-07-22 2006-03-02 Sequenom, Inc. Methods for identifying risk of type ii diabetes and treatments thereof
CA2584986A1 (en) * 2004-10-22 2006-05-04 Neurologix, Inc. Use of apoptosis inhibiting compounds in degenerative neurological disorders
PL1879623T3 (pl) * 2005-05-02 2013-03-29 Genzyme Corp Terapia genowa zaburzeń rdzenia kręgowego
KR20080080109A (ko) * 2005-11-04 2008-09-02 바이오겐 아이덱 엠에이 인코포레이티드 도파민성 뉴런의 신경돌기 성장 및 생존의 촉진 방법
PL2066791T3 (pl) * 2006-10-03 2013-02-28 Genzyme Corp Terapia Genowa do leczenia stwardnienia zanikowego bocznego i innych zaburzeń rdzenia kręgowego
EP2150117A4 (en) * 2007-05-02 2011-10-05 Mclean Hospital Corp METHODS AND COMPOSITIONS FOR MITOCHONDRIA REPLACEMENT THERAPY
WO2009020624A1 (en) * 2007-08-08 2009-02-12 The Board Of Trustees Of The University Of Alabama For And On Behalf Of The University Of Alabama Regulators of protein misfolding and neuroprotection and methods of use
MX2010010495A (es) * 2008-04-03 2010-10-15 Hoffmann La Roche Uso de variantes del factor de crecimiento similar a la insulina (igf-i) pegiladas para el tratamiento de trastornos neuromusculares.
WO2010071832A1 (en) 2008-12-19 2010-06-24 Nationwide Children's Hospital Delivery of polynucleotides across the blood brain barrier using recombinant aav9
WO2010088729A1 (en) * 2009-02-04 2010-08-12 University Of Tasmania Through The Menzies Research Institute Compositions and uses therefor
JP5879256B2 (ja) * 2009-05-02 2016-03-08 ジェンザイム・コーポレーション 神経変性障害のための遺伝子治療
CA2800375C (en) * 2010-05-27 2021-03-09 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
US20140147434A1 (en) * 2011-05-06 2014-05-29 Ecole Polytechnique Federale De Lausanne (Epfl) NCoR1 is a Physiological Modulator of Muscle Mass and Oxidative Function
US10815285B2 (en) * 2011-07-01 2020-10-27 University Of South Florida Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases
JP6253596B2 (ja) * 2012-02-16 2017-12-27 ザ ペン ステイト リサーチ ファンデーション アシル補酵素ａ：リゾカルジオリピン・アシル基転移酵素１（ａｌｃａｔ１）の発現、機能または活性の阻害物質を同定する方法
EP2895621B1 (en) * 2012-09-14 2020-10-21 Population Bio, Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
WO2014161095A1 (en) * 2013-04-04 2014-10-09 Crp40 Inc. Crp40 fragments for the treatment of neurological disorders
AU2014329606B2 (en) * 2013-10-01 2020-02-06 Dana-Farber Cancer Institute, Inc. Methods for the identification, assessment, prevention, and treatment of neurological disorders and diseases using Fndc5
US20170129930A1 (en) * 2014-06-19 2017-05-11 Board Of Trustees Of The University Of Arkansas Compositions and methods for modulating neuronal degeneration
US11027024B2 (en) * 2015-05-29 2021-06-08 University Of Iowa Research Foundation Methods of delivery of transgenes for treating brain diseases
CA2973891A1 (en) * 2016-07-21 2018-01-21 Stealth Biotherapeutics Corp Therapeutic compositions including modified creatine compounds and uses thereof to treat and prevent mitochondrial diseases and conditions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079269A2 (en) * 2000-04-18 2001-10-25 Merck Patent Gmbh Lipid binding protein 4
WO2002063008A2 (en) * 2001-02-08 2002-08-15 Incyte Genomics, Inc. Intracellular signaling molecules
US20040092715A1 (en) * 2002-02-07 2004-05-13 Li Ding Intracellular signaling molecules
CN104955836A (zh) * 2012-12-28 2015-09-30 安尼巴莱·亚历山德罗·普卡 Bpifb4蛋白的变体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COLIN D. BINGLE ET AL.: "Systematic nomenclature for the PLUNC/PSP/ BSP30/SMGB proteins as a subfamily of the BPI fold-containing superfamily" *
D ENIS F. KINANE ET AL.: "Human variability in innate immunity" *
李冬锦 等: "趋化因子受体CXCR家族在神经系统中的表达和功能研究进展" *

Also Published As

Publication number Publication date
JP2020531047A (ja) 2020-11-05
EP3668891A1 (en) 2020-06-24
US20210128681A1 (en) 2021-05-06
AU2018317807A1 (en) 2020-02-06
EP3668891B1 (en) 2023-07-26
ES2970198T3 (es) 2024-05-27
US12311009B2 (en) 2025-05-27
WO2019034723A1 (en) 2019-02-21
EP3668891C0 (en) 2023-07-26
CA3109159A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
Raulin et al. ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
JP6397391B2 (ja) 神経変性障害のための遺伝子治療
JP2022123145A (ja) 認知保護を提供しつつ疾患の発症及び進行を遅らせるための遺伝子治療を用いた神経変性疾患の治療方法
JP7637058B2 (ja) Ｇｒｎ関連成人発症性神経変性の治療のための組換えアデノ随伴ウイルス
CN110325219B (zh) 编码甲基-CpG结合蛋白2的重组腺相关病毒的鞘内递送
US20160256571A1 (en) Invention
JP2023540054A (ja) Ｇｒｎ関連成人発症性神経変性の治療のための組換えアデノ随伴ウイルス
EP3571298B1 (en) Treatment of krabbe disease with umbilical cord blood transplantion (ucbt) and increased galactocerebrosidase (galc) expression
CN111094327A (zh) Bpifb4蛋白的用于神经元疾病和损伤的vtft同种型
TW202045530A (zh) 腺相關病毒對ｃｌｎ３聚核苷酸的遞送
CN114040980A (zh) 可用于治疗克拉伯病的组合物
CN118401667A (zh) 用于治疗cdkl5缺乏症(cdd)的组合物
US20240025953A1 (en) Compositions and methods for inhibiting alpha-synuclein aggregation
US20190038774A1 (en) Compounds, compositions, and methods for using hla-f
HK40031704B (en) Vtft isoform of a bpifb4 protein for use in neuronal diseases and injuries
HK40031704A (en) Vtft isoform of a bpifb4 protein for use in neuronal diseases and injuries
US20240058476A1 (en) Treatment of lipodystrophy
WO2013184209A1 (en) Mif for use in methods of treating subjects with a neurodegenerative disorder
JP7832898B2 (ja) クラッベ病の治療に有用な組成物
US20260007774A1 (en) Aav-mediated delivery of rgs10 to microglia
US20240189452A1 (en) Recombinant Adeno-Associated Virus Encoding Methyl-CPG Binding Protein 2 for Treating PITT Hopkins Syndrome VIA Intrathecal Delivery

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20201201

Address after: Copenhagen, Denmark

Applicant after: Roxiant Ltd.

Address before: Italy Naples

Applicant before: LGV1 Co.,Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220725

Address after: Italy, Naples

Applicant after: LGV1 Co.,Ltd.

Address before: Copenhagen, Denmark

Applicant before: Roxiant Ltd.

TA01 Transfer of patent application right
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200501

WD01 Invention patent application deemed withdrawn after publication